- Home
- DVAX vs HYT Comparison
DVAX vs HYT Comparison
Compare DVAX & HYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- HYT
- Stock Information
- Founded
- DVAX 1996
- HYT 2003
- Country
- DVAX United States
- HYT United States
- Employees
- DVAX N/A
- HYT N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- HYT Finance Companies
- Sector
- DVAX Health Care
- HYT Finance
- Exchange
- DVAX Nasdaq
- HYT Nasdaq
- Market Cap
- DVAX 1.7B
- HYT 1.4B
- IPO Year
- DVAX 2004
- HYT N/A
- Fundamental
- Price
- DVAX $12.90
- HYT $9.82
- Analyst Decision
- DVAX Buy
- HYT
- Analyst Count
- DVAX 2
- HYT 0
- Target Price
- DVAX $22.00
- HYT N/A
- AVG Volume (30 Days)
- DVAX 1.3M
- HYT 443.0K
- Earning Date
- DVAX 11-07-2024
- HYT 01-01-0001
- Dividend Yield
- DVAX N/A
- HYT 9.61%
- EPS Growth
- DVAX N/A
- HYT N/A
- EPS
- DVAX 0.15
- HYT N/A
- Revenue
- DVAX $260,810,000.00
- HYT N/A
- Revenue This Year
- DVAX $21.64
- HYT N/A
- Revenue Next Year
- DVAX $19.81
- HYT N/A
- P/E Ratio
- DVAX $85.33
- HYT N/A
- Revenue Growth
- DVAX N/A
- HYT N/A
- 52 Week Low
- DVAX $9.74
- HYT $8.18
- 52 Week High
- DVAX $15.01
- HYT $9.91
- Technical
- Relative Strength Index (RSI)
- DVAX 57.32
- HYT 40.74
- Support Level
- DVAX $12.66
- HYT $9.86
- Resistance Level
- DVAX $13.17
- HYT $9.95
- Average True Range (ATR)
- DVAX 0.29
- HYT 0.06
- MACD
- DVAX -0.04
- HYT -0.01
- Stochastic Oscillator
- DVAX 48.08
- HYT 8.00
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About HYT Blackrock Corporate High Yield Fund Inc.
BlackRock Corporate High Yield Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income and capital appreciation. The trust's secondary investment objective is to provide shareholders with capital appreciation. It seeks to achieve its objectives by investing in a diversified portfolio of fixed-income securities.